Clinical validation of C1-INH complex assays

Clinical validation of C1-INH complex assays in: COVID-19 and MIS-C 

Hycult Biotech has developed new ELISA kits to monitor early classical pathway activation (via C1s/C1-INH complex), or early lectin pathway activation (via MASP-1/C1-INH complex). The tools are useful to investigate and unravel early complement activation in complement-mediated diseases.

C1-INH complexes and complement activation in COVID-19 and MIS-C. In two recent studies the C1-INH complex assay have been clinically validated:

1. Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1INH complexes using novel ELISAs 
2. Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children

Assay benefits:

• Uses EDTA-plasma as input sample. No need for complement-preserved serum to assess early lectin pathway activation
• Ready-to-use ELISA with a working time of 1 hour and 45 minutes
• First on the market available ELISA assay to measure early classical and early lectin pathway activation

Other diseases of interest for C1-INH and its complexes:
C1-INH administration is an approved common treatment for hereditary angioedema (HAE) and in clinical trials for:

• Prevention of rejection in kidney transplantation
• Traumatic brain injury and acute ischemic stroke
• Endotoxemia, sepsis, inflammation and multiple organ failure
• Application in end stage renal disease and chronic kidney disease